An introduction to economic studies, health emergencies, and COVID-19.
COVID-19
disaster risk management
economic evaluation
economic impact study
health emergency
Journal
Journal of evidence-based medicine
ISSN: 1756-5391
Titre abrégé: J Evid Based Med
Pays: England
ID NLM: 101497477
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
20
04
2020
accepted:
08
05
2020
entrez:
30
5
2020
pubmed:
30
5
2020
medline:
10
6
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic has created widespread harm and disruption. Countries have implemented unprecedented measures to protect the lives and livelihoods of their inhabitants. The scope and composition of these responses are shaped, in part, by research and analysis about the estimated economic impacts of the COVID-19 Pandemic and proposed responses to it. This analysis outlines basic features and principles involved in economic studies, specifically economic impact studies and economic evaluations, which have formed a significant part of the ever-increasing evidence base about COVID-19. This analysis introduces economic studies in this context, highlighting what they can do, their limitations, and key steps involved in conducting them. It highlights examples of economic analysis focused on COVID-19 and on health emergencies and disasters more broadly. Knowing how economic studies are conducted, and their limitations, will help introduce how their findings can be a useful, usable, and used part of efforts to tackle this global health crisis.
Identifiants
pubmed: 32470229
doi: 10.1111/jebm.12395
pmc: PMC7283784
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-167Informations de copyright
© 2020 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.
Références
J Infect Dis. 2018 Nov 22;218(suppl_5):S698-S704
pubmed: 30321368
PLoS One. 2016 Jan 28;11(1):e0147052
pubmed: 26820982
J Evid Based Med. 2020 May;13(2):161-167
pubmed: 32470229
J R Soc Interface. 2011 Sep 7;8(62):1307-13
pubmed: 21296791
Pathog Glob Health. 2015 Feb;109(1):4-9
pubmed: 25578284
Hum Vaccin Immunother. 2013 Jul;9(7):1500-11
pubmed: 23732900
J Glob Health. 2019 Jun;9(1):010406
pubmed: 30701070
Health Syst Reform. 2019;5(4):307-321
pubmed: 31661356
Health Policy Plan. 2020 Feb 1;35(1):107-114
pubmed: 31625564
Risk Anal. 2011 Jul;31(7):1107-19
pubmed: 21303401
Health Secur. 2020 Jan;18(S1):S53-S63
pubmed: 32004126
Int J Environ Res Public Health. 2016 Nov 08;13(11):
pubmed: 27834843
Value Health. 2017 Jun;20(6):819-827
pubmed: 28577700
Bull World Health Organ. 2018 Feb 1;96(2):129-134
pubmed: 29403116
Diabetes Care. 2009 Sep;32(9):1632-8
pubmed: 19542210
Lancet Infect Dis. 2019 Aug;19(8):e295-e300
pubmed: 31006605
Value Health. 2016 Dec;19(8):921-928
pubmed: 27987641
Eur J Health Econ. 2013 Jun;14(3):367-72
pubmed: 23526140
Value Health. 2018 Feb;21(2):161-165
pubmed: 29477394
Health Secur. 2019 Mar/Apr;17(2):100-108
pubmed: 30969152
PLoS Comput Biol. 2017 Jun 1;13(6):e1005521
pubmed: 28570660